Top 5 Target	Count

EZH2(Histone-lysine N-methyltransferase EZH2)	2
Bcr-Abl T315I(BCR-ABL T315I mutation)	2
FLT3(Tyrosine-protein kinase receptor FLT3)	1
WEE1(Serine/threonine-protein kinase WEE1)	1
Bcr-Abl V299L	1

Drugs associated with Hefei Institutes of Physical Science

Adavosertib

Target

WEE1

Mechanism

WEE1 inhibitors

Active Org.

AstraZeneca PLC [+2]

Originator Org.

Merck & Co., Inc.

Active Indication

Uterine Carcinosarcoma [+9]

Inactive Indication

Advanced Gastric Adenocarcinoma [+15]

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date-

Lunresertib

Target

CCNE1 x PKMYT1

Mechanism

CCNE1 inhibitors [+1]

Active Org.

Canadian Cancer Trials Group [+6]

Originator Org.

Repare Therapeutics, Inc.

Active Indication

ER-positive/HER2-negative Breast Cancer [+17]

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date-

HYML-122

Target

FLT3

Mechanism

FLT3 inhibitors

Active Org.

Tarapeutics Science Inc [+2]

Originator Org.

Hefei Institutes of Physical Science [+1]

Active Indication

Refractory acute myeloid leukemia [+2]

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Hefei Institutes of Physical Science

CTR20211957

/ RecruitingPhase 2

评价HYML-122片联合阿糖胞苷治疗FLT3突变复发或难治性的急性髓系白血病（AML）患者的有效性和安全性的单臂、开放、多中心临床试验

[Translation] A single-arm, open-label, multicenter clinical trial to evaluate the efficacy and safety of HYML-122 tablets combined with cytarabine in the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations

主要目的：评价HYML-122片联合阿糖胞苷治疗FLT3突变复发或难治性的急性髓系白血病（AML）的有效性，探索最佳给药方案，为Ⅲ期临床试验提供设计依据。次要目的：1)评估HYML-122片在人体内不同给药方案药代动力学特征；2)通过其它次要疗效指标，观察和评价疗效差异；3)观察和评价安全性，包括临床症状体征观察和实验室指标，AE（和SAE）的发生率和严重程度。

[Translation]

Primary objective: To evaluate the efficacy of HYML-122 tablets combined with cytarabine in the treatment of relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation, explore the optimal dosing regimen, and provide a design basis for Phase III clinical trials. Secondary objectives: 1) To evaluate the pharmacokinetic characteristics of HYML-122 tablets in different dosing regimens in humans; 2) To observe and evaluate the efficacy differences through other secondary efficacy indicators; 3) To observe and evaluate safety, including clinical symptoms and signs observation and laboratory indicators, the incidence and severity of AEs (and SAEs).

Start Date29 Mar 2022

Sponsor / Collaborator

Hefei Institutes of Physical Science

[+1]

CTR20211928

/ RecruitingPhase 2

评价HYML-122片单药治疗FLT3突变复发或难治性的急性髓系白血病（AML）患者的有效性和安全性的单臂、开放、多中心临床试验

[Translation] A single-arm, open-label, multicenter clinical trial to evaluate the efficacy and safety of HYML-122 tablets as a monotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations

主要目的：评价HYML-122片单药治疗FLT3突变复发或难治性的急性髓系白血病（AML）的有效性，探索最佳给药方案，为Ⅲ期临床试验提供设计依据。次要目的：1) 评估HYML-122片在人体内不同给药方案药代动力学特征；2) 通过其它次要疗效指标，观察和评价疗效差异； 3) 观察和评价安全性，包括临床症状体征观察和实验室指标，AE（和SAE）的发生率和严重程度

[Translation]

Primary purpose: To evaluate the efficacy of HYML-122 tablets as a single agent in the treatment of relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation, explore the best dosing regimen, and provide a design basis for Phase III clinical trials. Secondary objectives: 1) To evaluate the pharmacokinetic characteristics of HYML-122 tablets in different dosing regimens in humans; 2) To observe and evaluate the efficacy differences through other secondary efficacy indicators; 3) To observe and evaluate safety, including clinical symptoms and signs observation and laboratory indicators, the incidence and severity of AEs (and SAEs).

Start Date26 Sep 2021

Sponsor / Collaborator

Hefei Institutes of Physical Science

[+1]

ISRCTN12308193

/ RecruitingNot ApplicableIIT

Non-invasive and accurate diagnosis of type 2 diabetes using urinary acetone: a prospective multicenter study

Start Date20 Apr 2021

Sponsor / Collaborator

Hefei Institutes of Physical Science

100 Clinical Results associated with Hefei Institutes of Physical Science

0 Patents (Medical) associated with Hefei Institutes of Physical Science

4,309

Literatures (Medical) associated with Hefei Institutes of Physical Science

01 Dec 2025·Molecular Biology Reports

Synergistic inhibitory effect of atmospheric pressure plasma and berberine on non‑small cell lung cancer cells via inducing apoptosis

Article

Author: Ming, Huiyun ; Song, Wencheng ; Zhou, Han ; Dai, Haiming ; Lu, Tingting

BACKGROUNDNon-small cell lung cancer (NSCLC) is a type of lung cancer, the incidence and mortality rate have been high, and the use of monotherapy is easy to make patients develop tolerance. Atmospheric pressure plasma (APP) is an emerging technology for killing cancer cells in recent years, and combination of berberine (BBR) mechanism has not been fully elucidated for NSCLC. The article's primary goal is to investigate the effect of combination on NSCLC and its associated characterization.METHODS AND RESULTSAntiproliferative effects were detected by cell viability assay and colony formation, and flow cytometry analysis of apoptosis and cycling showed that the combination synergistically induced apoptosis. Then, extracellular reactive oxygen species (ROS)levels and DCFH-DA-based kits examined intracellular ROS levels, and their effects on mitochondrial membrane potential were measured. Study reveals that co-induced apoptosis is associated with ROS accumulation. Subsequently, Western blotting (WB) detected the expression of epidermal growth factor receptor (EGFR), and the important signaling pathway proteins Ras/ERK and AKT/mTOR. Results showed that it could downregulation of EGFR protein expression and inhibit of activation of ERK/AKT signaling pathways. Simultaneous wound healing assay and epithelial-to-mesenchymal transition (EMT) marker detection were performed for the assessment of migration and EMT ability of NSCLC cells. Combination therapy inhibited migration and EMT of NSCLC cells.CONCLUSIONThe results of this study show that the combination can synergistically induce apoptosis of NSCLC by regulating ROS production. EGFR downregulation and AKT/ERK signaling pathway inhibition are linked to the synergistic effect.

01 Oct 2025·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Identification and quantification of low concentration phenol and toluene in groundwater by fluorescence spectroscopy with Gaussian feature extraction

Article

Author: Shi, Gaoyong ; Song, Hengxin ; Zhao, Nanjing ; Yang, Ruifang ; Huang, Peng ; Jiang, Yuxi ; Gao, Ming ; Yin, Gaofang

Groundwater, a vital freshwater resource, faces increasing contamination risks from chemical industrial parks discharging hazardous compounds such as phenol and toluene. Detecting these pollutants at low concentrations is essential to ensure water quality and protect against long-term hazards. A method combining fluorescence spectroscopy and Gaussian feature extraction is proposed for the identification and quantification of phenol and toluene in groundwater. Fluorescence excitation-emission matrix (EEM) spectra of phenol and toluene are first measured, followed by feature extraction using a Gaussian function. The extracted features are then employed for qualitative identification and quantitative determination via support vector machine (SVM) and partial least squares (PLS) regression, respectively. For qualitative identification, Gaussian feature extraction is compared with original feature and PCA-based feature extraction methods. For quantification, it is compared with peak picking and PCA-based feature extraction methods. The results show that after Gaussian feature extraction, the performance is significantly improved. The identification accuracy for single-component samples reached 95.24 %, while for mixture samples, the accuracy was 90 %. In quantitative analysis of mixture samples, the average relative error for phenol concentrations of 2 µg/L or higher and toluene concentrations of 600 µg/L was controlled around 10 %, while for phenol concentrations at 1 µg/L, the relative error was about 30 %. This approach enhances both identification and quantification performance, providing a reliable tool for the early detection and quantification of low-concentration contaminants in groundwater, with great potential for environmental protection.

01 Sep 2025·Journal of Environmental Sciences

Explosive growth characteristics of 5.6–560 nm particles and deposition in human respiratory during spring in Yangtze River Delta region, China

Article

Author: Wang, Xinqi ; Ji, Xiangguang ; Wang, Danni ; Guan, Lixin ; Hu, Qihou ; Zhang, Chao ; Ou, Jinping ; Gong, Yingru ; Zhu, Yizhi ; Liu, Cheng ; Xing, Chengzhi ; Wan, Yuhui ; Feng, Jiaxuan

Studying the contribution of regional transport to ultrafine particles (UFPs) and the deposition effect of nanoscale particles in human respiratory system is conducive to exploring the impact of atmospheric particles on the environment and human health. Based on the data set of number concentration spectrum in the particle size range of 5.6-560 nm in the spring of Hefei, the Yangtze River Delta region obtained by a fast mobility particle sizer, the explosive growth characteristics, potential source identification and deposition flux analysis of UFPs were systematically studied. The results showed that the frequency of new particle formation (NPF) events during spring was 31.5 %. SO₂ and O₃ contribute to NPF events. Daytime, higher temperature, stronger solar radiation and lower humidity were more conducive to the explosive growth of UFPs. In addition, regional transport of pollutants from the cities around Hefei played an important role in the accumulation mode particles, which were mainly affected by the land-source air mass from northwest Jiangsu (23.64 %) and the sea-source air mass from the Yellow Sea (23.99 %). It was worth noting that approximately 10,406 ng of UFPs enters the human respiratory system every day. The main deposition area of 5.6-560 nm nanoscale particles was alveolar, 5.6-400 nm is more likely to be deposited on alveolar, while nanoscale particles with particle size between 400 and 560 nm is more likely to be deposited on head airways. This study identified the deposition risk of nanoscale particles in the respiratory system under different particle sizes.

100 Deals associated with Hefei Institutes of Physical Science

100 Translational Medicine associated with Hefei Institutes of Physical Science

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 10 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Preclinical

Phase 2 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

HYML-122 ( FLT3 )	FLT3 positive Acute Myeloid Leukemia More	Phase 2
CHMFL-VEGFR2-002 ( VEGFR2 )	Neoplasms More	Preclinical
ROR1 targeted ADC (Hefei Institutes of Physical Science) ( ROR1 )	Neoplasms More	Preclinical
CHMFL-48 ( Bcr-Abl T315I )	BCR-ABL Negative Atypical Chronic Myeloid Leukemia More	Preclinical
IHMT-EZH-2-115 ( EZH2 )	B-Cell Lymphoma More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis